PAP CAR-T细胞疗法是斯丹赛基于自主研发的CoupledCAR平台技术开发的产品管线之一，用于治疗难治性前列腺癌患者。摘要信息 摘要标题 ：A Phase I clinical trial evaluating the safety and preliminary efficacy of PAP CAR-T cells for the treatment of desmoplasia-resistant prostate cancer(PAP CAR-T细胞疗法治疗难...
[2]Stephen J. Freedland, et al. 609P - Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019 2021 ESMO Poster 609P [3]Pilon D, et at. Presented at AMCP Nexus; October 18-21, 2021 *此文仅用于向医学人士提供科学信息,不...
PAP CAR-T细胞疗法是斯丹赛基于自主研发的CoupledCAR平台技术开发的产品管线之一,用于治疗难治性前列腺癌患者。 摘要信息 摘要标题:A Phase I clinical trial evaluating the safety and preliminary efficacy of PAP CAR-T cells for the treatment of desmoplasia-resistant prostate cancer(PAP CAR-T细胞疗法治疗难治性...
[34] Payne H, Cornford P. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol. 2011 Nov-Dec;29(6):593-601. [35] Pannek J, Partin AW. The...
PAP CAR-T细胞疗法是斯丹赛基于自主研发的CoupledCAR平台技术开发的产品管线之一,用于治疗难治性前列腺癌患者。 摘要信息 摘要标题 :A Phase I clinical trial evaluating the safety and preliminary efficacy of PAP CAR-T cells for the treatment of desmoplasia-resistant prostate cancer(PAP CAR-T细胞疗法治疗难...
Results: All prostate cancer patients had highly variable serum PSA values ranging from 12.90 ng/mL to 193.5 ng/mL. The post treatment PSA analysis revealed that the increase level of PSA (15%) which showed that the PSA level increased after the treatment. Whereas in all other 17 patients ...
[2]Stephen J. Freedland, et al. 609P - Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019 2021 ESMO Poster 609P [3]Pilon D, et at. Presented at AMCP Nexus; October 18-21, 2021...
A PSA test can screen for prostate cancer or show how well treatment worked. Find out when you'll have this test, and what your results could mean.
摘要标题 :A Phase I clinical trial evaluating the safety and preliminary efficacy of PAP CAR-T cells for the treatment of desmoplasia-resistant prostate cancer(PAP CAR-T细胞疗法治疗难治性前列腺癌的安全性和初步有效性评估的I期临床试验研究)
Background: This study was designed to suggest the possibility of hormone-related derangement in salvage radiotherapy (SRT) a er radical prostatectomy in terms of prostate-specific an gen (PSA) control. Materials and Methods: Among 160 consecu ve prostate cancer pa ents who received radical prostat...